Loading patent…
AssigneesBeth Israel Deaconess Medical Center, Inc., The Brigham and Women's Hospital, Inc.
InventorsChristopher V. CARMAN, Roberta MARTINELLI, Thomas MICHEL, Hermann KALWA
Estimating the term…
The invention features methods, devices, pharmaceutical compositions, and kits for treating or preventing acute vascular leak. Such methods may involve contacting an effective amount of bosutinib for treating or preventing acute vascular leak with a subject in need thereof. Conditions associated with acute vascular leak include ischemic brain injury, stroke, septic shock, anthrax lethal toxin, anaphylaxis, trauma, severe episodic vasculitis, acute lung injury, ventilator-induced lung injury, transfusion-related acute lung injury, acute respiratory distress syndrome, severe burn injury, circulatory shock, capillary leak syndrome, and ischemia-reperfusion injury. The invention also features automatic injection devices, resuscitation fluids, or pharmaceutical compositions comprising an effective amount of bosutinib for treating or preventing acute vascular leak. The invention further features kits for use in the methods of the invention.
A method of treating or preventing acute vascular leak in a subject in need thereof, wherein said method comprises contacting an effective amount of bosutinib with said subject, and wherein said acute vascular leak is associated with a condition selected from the group consisting of:
(canceled)
4-5. (canceled)
8-10. (canceled)
14-27. (canceled)
A method of treating vascular leak in a subject identified as likely to benefit from bosutinib treatment by monitoring one or more measures reflective of vascular leak, said method comprising
(canceled)
(canceled)
40-42. (canceled)
A pharmaceutical composition in unit dosage form comprising an effective amount of bosutinib for treating or preventing acute vascular leak, wherein said unit dosage form comprises:
44-48. (canceled)
52-56. (canceled)
58-59. (canceled)
Dependencies are inferred from the claim text.